Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2019 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma

– Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater...
August 07, 2019 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
August 01, 2019 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update

- Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing – – Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration – –...
July 25, 2019 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report Second Quarter 2019 Financial Results

SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
July 24, 2019 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
July 11, 2019 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents

SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
June 21, 2019 16:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

SAN DIEGO, June 21, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 18, 2019 23:31 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock

SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 18, 2019 16:01 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Commencement of Public Offering of Common Stock

SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 14, 2019 07:00 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma

– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an...

Next Page keyboard_arrow_right